Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy
BACKGROUND We developed a new anti‐cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinoma of mice (TRAMP). METHODS Mice with 5, 10, and 13 mm in diameter intra...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2006-11, Vol.66 (15), p.1620-1630 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1630 |
|---|---|
| container_issue | 15 |
| container_start_page | 1620 |
| container_title | The Prostate |
| container_volume | 66 |
| creator | Plotnikov, Alexander Niego, Be'eri Ophir, Rachel Korenstein, Rafi Keisari, Yona |
| description | BACKGROUND
We developed a new anti‐cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinoma of mice (TRAMP).
METHODS
Mice with 5, 10, and 13 mm in diameter intracutaneous tumors received Low Electric Field Cancer Treatment‐Enhanced Chemotherapy (LEFCT‐EC) with doxorubicin (10 mg/kg), and monitored for survival, and primary and metastatic tumors growth.
RESULTS
The electric field increased the uptake of doxorubicin by TRAMP cells in vitro. In vivo use of LEFCT‐EC reduced tumor size, prolonged survival, and cured 36–93% of the animals, dependent on treated tumor size. LEFCT‐EC was more effective than surgery with or without chemotherapy. Part of the cured animals developed anti‐tumor immunity and immunosuppression, significantly decreased the effectiveness of the treatment.
CONCLUSION
Our results suggest that LEFCT‐EC is an effective method for the destruction of metastatic prostate tumors. Prostate 66: 1620–1630, 2006. © 2006 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/pros.20435 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68896532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68896532</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3915-304786a1279f50a374733b281ff11ded5a6eda5d054225e9748da160bb1baaae3</originalsourceid><addsrcrecordid>eNp9kEFv1DAQhS0Eokvhwg9AvsABKWVsx3ZyRFUpiIoiWgTqxZo4Y20g2Sy2l7L_Hi-70BsnW5rvzZv3GHsq4EQAyFfrOKcTCbXS99hCQGsrgFrfZwuQFqpaKHvEHqX0DaDgIB-yI2HaWtTGLJg_C4F8Hn4Sz5EwT7TKfA58mjeJ-EQZU8Y8eL4zKT_iHleeIu-2fJxvOY1FHcs8DDT2nFbL3bjnfknTnJcUcb19zB4EHBM9ObzH7PObs-vTt9XF5fm709cXlVet0JWC2jYGhbRt0IDK1lapTjYiBCF66jUa6lH3oGspNbW2bnoUBrpOdIhI6pi92O8tt_7YUMpuGpKnccQVlTjONE1rtJIFfLkHfQmVIgW3jsOEcesEuF2lbpfW_am0wM8OWzfdRP0deuiwAM8PACaPY4ilgSHdcY3U5WJVOLHnboeRtv-xdB8_XV79Na_2miFl-vVPg_G7M1ZZ7b58OHftdXPz9Qau3Hv1G30Hnu4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68896532</pqid></control><display><type>article</type><title>Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Plotnikov, Alexander ; Niego, Be'eri ; Ophir, Rachel ; Korenstein, Rafi ; Keisari, Yona</creator><creatorcontrib>Plotnikov, Alexander ; Niego, Be'eri ; Ophir, Rachel ; Korenstein, Rafi ; Keisari, Yona</creatorcontrib><description>BACKGROUND
We developed a new anti‐cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinoma of mice (TRAMP).
METHODS
Mice with 5, 10, and 13 mm in diameter intracutaneous tumors received Low Electric Field Cancer Treatment‐Enhanced Chemotherapy (LEFCT‐EC) with doxorubicin (10 mg/kg), and monitored for survival, and primary and metastatic tumors growth.
RESULTS
The electric field increased the uptake of doxorubicin by TRAMP cells in vitro. In vivo use of LEFCT‐EC reduced tumor size, prolonged survival, and cured 36–93% of the animals, dependent on treated tumor size. LEFCT‐EC was more effective than surgery with or without chemotherapy. Part of the cured animals developed anti‐tumor immunity and immunosuppression, significantly decreased the effectiveness of the treatment.
CONCLUSION
Our results suggest that LEFCT‐EC is an effective method for the destruction of metastatic prostate tumors. Prostate 66: 1620–1630, 2006. © 2006 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.20435</identifier><identifier>PMID: 16941466</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - secondary ; Animals ; Antibiotics, Antineoplastic - pharmacokinetics ; Antibiotics, Antineoplastic - therapeutic use ; Biological and medical sciences ; Cell Line, Tumor ; chemotherapy ; Disease Models, Animal ; Doxorubicin - pharmacokinetics ; Doxorubicin - therapeutic use ; Drug Screening Assays, Antitumor ; Electrochemotherapy ; Electroporation ; electrostimulation ; Gynecology. Andrology. Obstetrics ; immunostimulation ; low electric field ; Male ; Male genital diseases ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Neoplasm Transplantation ; Nephrology. Urinary tract diseases ; prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Spleen - drug effects ; Survival Rate ; Treatment Outcome ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2006-11, Vol.66 (15), p.1620-1630</ispartof><rights>Copyright © 2006 Wiley‐Liss, Inc.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3915-304786a1279f50a374733b281ff11ded5a6eda5d054225e9748da160bb1baaae3</citedby><cites>FETCH-LOGICAL-c3915-304786a1279f50a374733b281ff11ded5a6eda5d054225e9748da160bb1baaae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.20435$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.20435$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18255423$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16941466$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Plotnikov, Alexander</creatorcontrib><creatorcontrib>Niego, Be'eri</creatorcontrib><creatorcontrib>Ophir, Rachel</creatorcontrib><creatorcontrib>Korenstein, Rafi</creatorcontrib><creatorcontrib>Keisari, Yona</creatorcontrib><title>Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
We developed a new anti‐cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinoma of mice (TRAMP).
METHODS
Mice with 5, 10, and 13 mm in diameter intracutaneous tumors received Low Electric Field Cancer Treatment‐Enhanced Chemotherapy (LEFCT‐EC) with doxorubicin (10 mg/kg), and monitored for survival, and primary and metastatic tumors growth.
RESULTS
The electric field increased the uptake of doxorubicin by TRAMP cells in vitro. In vivo use of LEFCT‐EC reduced tumor size, prolonged survival, and cured 36–93% of the animals, dependent on treated tumor size. LEFCT‐EC was more effective than surgery with or without chemotherapy. Part of the cured animals developed anti‐tumor immunity and immunosuppression, significantly decreased the effectiveness of the treatment.
CONCLUSION
Our results suggest that LEFCT‐EC is an effective method for the destruction of metastatic prostate tumors. Prostate 66: 1620–1630, 2006. © 2006 Wiley‐Liss, Inc.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - secondary</subject><subject>Animals</subject><subject>Antibiotics, Antineoplastic - pharmacokinetics</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cell Line, Tumor</subject><subject>chemotherapy</subject><subject>Disease Models, Animal</subject><subject>Doxorubicin - pharmacokinetics</subject><subject>Doxorubicin - therapeutic use</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Electrochemotherapy</subject><subject>Electroporation</subject><subject>electrostimulation</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>immunostimulation</subject><subject>low electric field</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neoplasm Transplantation</subject><subject>Nephrology. Urinary tract diseases</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Spleen - drug effects</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFv1DAQhS0Eokvhwg9AvsABKWVsx3ZyRFUpiIoiWgTqxZo4Y20g2Sy2l7L_Hi-70BsnW5rvzZv3GHsq4EQAyFfrOKcTCbXS99hCQGsrgFrfZwuQFqpaKHvEHqX0DaDgIB-yI2HaWtTGLJg_C4F8Hn4Sz5EwT7TKfA58mjeJ-EQZU8Y8eL4zKT_iHleeIu-2fJxvOY1FHcs8DDT2nFbL3bjnfknTnJcUcb19zB4EHBM9ObzH7PObs-vTt9XF5fm709cXlVet0JWC2jYGhbRt0IDK1lapTjYiBCF66jUa6lH3oGspNbW2bnoUBrpOdIhI6pi92O8tt_7YUMpuGpKnccQVlTjONE1rtJIFfLkHfQmVIgW3jsOEcesEuF2lbpfW_am0wM8OWzfdRP0deuiwAM8PACaPY4ilgSHdcY3U5WJVOLHnboeRtv-xdB8_XV79Na_2miFl-vVPg_G7M1ZZ7b58OHftdXPz9Qau3Hv1G30Hnu4</recordid><startdate>200611</startdate><enddate>200611</enddate><creator>Plotnikov, Alexander</creator><creator>Niego, Be'eri</creator><creator>Ophir, Rachel</creator><creator>Korenstein, Rafi</creator><creator>Keisari, Yona</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200611</creationdate><title>Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy</title><author>Plotnikov, Alexander ; Niego, Be'eri ; Ophir, Rachel ; Korenstein, Rafi ; Keisari, Yona</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3915-304786a1279f50a374733b281ff11ded5a6eda5d054225e9748da160bb1baaae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - secondary</topic><topic>Animals</topic><topic>Antibiotics, Antineoplastic - pharmacokinetics</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cell Line, Tumor</topic><topic>chemotherapy</topic><topic>Disease Models, Animal</topic><topic>Doxorubicin - pharmacokinetics</topic><topic>Doxorubicin - therapeutic use</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Electrochemotherapy</topic><topic>Electroporation</topic><topic>electrostimulation</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>immunostimulation</topic><topic>low electric field</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neoplasm Transplantation</topic><topic>Nephrology. Urinary tract diseases</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Spleen - drug effects</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Plotnikov, Alexander</creatorcontrib><creatorcontrib>Niego, Be'eri</creatorcontrib><creatorcontrib>Ophir, Rachel</creatorcontrib><creatorcontrib>Korenstein, Rafi</creatorcontrib><creatorcontrib>Keisari, Yona</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Plotnikov, Alexander</au><au>Niego, Be'eri</au><au>Ophir, Rachel</au><au>Korenstein, Rafi</au><au>Keisari, Yona</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2006-11</date><risdate>2006</risdate><volume>66</volume><issue>15</issue><spage>1620</spage><epage>1630</epage><pages>1620-1630</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
We developed a new anti‐cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinoma of mice (TRAMP).
METHODS
Mice with 5, 10, and 13 mm in diameter intracutaneous tumors received Low Electric Field Cancer Treatment‐Enhanced Chemotherapy (LEFCT‐EC) with doxorubicin (10 mg/kg), and monitored for survival, and primary and metastatic tumors growth.
RESULTS
The electric field increased the uptake of doxorubicin by TRAMP cells in vitro. In vivo use of LEFCT‐EC reduced tumor size, prolonged survival, and cured 36–93% of the animals, dependent on treated tumor size. LEFCT‐EC was more effective than surgery with or without chemotherapy. Part of the cured animals developed anti‐tumor immunity and immunosuppression, significantly decreased the effectiveness of the treatment.
CONCLUSION
Our results suggest that LEFCT‐EC is an effective method for the destruction of metastatic prostate tumors. Prostate 66: 1620–1630, 2006. © 2006 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16941466</pmid><doi>10.1002/pros.20435</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2006-11, Vol.66 (15), p.1620-1630 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68896532 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - secondary Animals Antibiotics, Antineoplastic - pharmacokinetics Antibiotics, Antineoplastic - therapeutic use Biological and medical sciences Cell Line, Tumor chemotherapy Disease Models, Animal Doxorubicin - pharmacokinetics Doxorubicin - therapeutic use Drug Screening Assays, Antitumor Electrochemotherapy Electroporation electrostimulation Gynecology. Andrology. Obstetrics immunostimulation low electric field Male Male genital diseases Medical sciences Mice Mice, Inbred C57BL Neoplasm Transplantation Nephrology. Urinary tract diseases prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Spleen - drug effects Survival Rate Treatment Outcome Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A25%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20treatment%20of%20mouse%20metastatic%20prostate%20cancer%20by%20low%20electric%20field%20enhanced%20chemotherapy&rft.jtitle=The%20Prostate&rft.au=Plotnikov,%20Alexander&rft.date=2006-11&rft.volume=66&rft.issue=15&rft.spage=1620&rft.epage=1630&rft.pages=1620-1630&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.20435&rft_dat=%3Cproquest_cross%3E68896532%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68896532&rft_id=info:pmid/16941466&rfr_iscdi=true |